A-SKIN Nederland BV
De Boelelaan 1117
1081 HV Amsterdam
Website A-SKIN Nederland BV
E-mail A-SKIN Nederland BV
T +31 (0)20 444 26 24
F +31 (0)20 444 29 64

Employees in Amsterdam: 6
Employees in R&D: 3
Year of foundation: 2006

Company Profile

A-SKIN Nederland BV is a start-up from VUmc Amsterdam, and is positioned as a tissue engineering service company developing and commercialising autologous skin products from her GMP skin culture laboratory. Current customers are located in hospitals, out-patient clinics and (long term) care facilities in the Netherlands. In the coming years the patented A-SKIN autologous skin culture technique and related products will be made available trough out-licensing and daughter companies in other European countries and beyond.
With Tiscover® A-SKIN Nederland BV offers patients and professionals a novel and superior product for healing chronic, inert skin wounds. This product fills an unmet medical need in the treatment of various skin ulcers such as due to decubitus, diabetes or vascular malfunctioning.

Science and Technologies or Services

Alliances

• VU medical centre, Amsterdam
• Euro Skin Bank, Beverwijk
• Brandwonden centrum, Beverwijk

Keywords

• Tissue culturing
• Biomaterials
• Skin wounds
• Chronic leg ulcers
• Venous leg ulcers
• Decubitus ulcers
• Diabetic ulcers
  
  

Agendia B.V.
Science Park 406
1098 XH Amsterdam
Website Agendia B.V. 
E-mail Agendia B.V.
Promotion video Agendia
T +31 (0)20 462 15 00
F +31 (0)20 462 15 05

Employees in Amsterdam: 65
Employees in R&D: 9
Year of foundation: 2003

Company Profile

Agendia is committed to improving the quality of life of people suffering from cancer. The company is a world leader in gene expression analysis-based diagnostics and has developed a series of validated, state of the art tests using tumor gene expression profiling. The tests help oncologists make the right decision regarding the treatment of the individual cancer patient. Agendia was the first company to commercialise a prognostic test, MammaPrint, which predicts the risk of breast cancer recurrence. MammaPrint was cleared by the US Food and Drugs administration in February 2007.
Agendia was founded in 2003 by Netherlands Cancer Institute (NKI) researchers Laura van 't Veer, René Bernards and Bernhard Sixt and is located in Amsterdam in the Netherlands. Agendia is now in the market with three products: MammaPrint, CupPrint and DiscoverPrint.

Science and Technologies or Services

Agendia has developed high-quality diagnostic methods using microarray gene expression profiling to determine tumor specific properties. Our in vitro diagnostic laboratory services offered to physicians and pharmaceutical companies improve the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.

Alliances

• Netherlands Cancer Institute

Keywords

• Gene expression analysis
• Genomic profiling
• Microarray
• Cancer
• Diagnostic
• MammaPrint
• CupPrint
• DiscoverPrint
  
  

AIMM Therapeutics B.V.
Meibergdreef 45
1105 BA Amsterdam
Website AIMM Therapeutics B.V.
E-mail AIMM Terapeutics B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 58

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2005

Company Profile

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.

Science and Technologies or Services

The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.

Alliances

• AMC-Amsterdam;
• UMCU-Utrecht;
• NVI-Bilthoven.

Keywords

• Human antibodies;
• Vaccines.

AM-Pharma B.V.
Rumpsterweg 6
3981 AK Bunnik
Website AM-Pharma B.V.
E-mail AM-pharma B.V.
T +31 (0)30 228 92 22
F +31 (0)30 228 92 20

Employees in Amsterdam: 17
Employees in R&D: 17
Year of foundation: 2000

Company Profile

AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. All our products address high medical needs and commercially attractive markets.
Our products are based on endogenous proteins and (protein derived) peptides, optimised to fight inflammatory diseases and infections. AM-Pharma has intellectual property around two scientific platforms:

• Enhancing Toll Like Receptor mediated activation of innate immune cells
• Dephosphorylation of extracellular substrates to influence disease processes

So far, AM-Pharma has developed two products originating from its intellectual property franchise, Alkaline Phosphatase and hLF1-11 up to the point of initial proof of clinical efficacy and safety.
AM-Pharma currently employs 17 people. We out-source all non-core know how dependent development work to specialist third party organisations.
Once our products have shown to be safe and effective in patients we out-license our products to collaboration partners who become responsible for further development and worldwide marketing.

Science and Technologies or Services

Alkaline Phosphatase (AP) (acute renal failure and ulcerative colitis)
The endogenous enzyme alkaline phosphatase is expressed in various tissues throughout the human body including kidney and GI tract. AP has been shown to dephosphorylate LPS to a non-toxic form that acts as a partial antagonist on the LPS receptor complex. In addition to LPS, AP can dephosphorylate different other substrates e.g. ATP and through this dephosphorylation interfere with inflammatory response and associated tissue damage. Proof of concept has been shown in Phase IIa Proof Of Concept trials in Acute Renal Failure and Ulcerative Colitis.

HLF 1-11 Anti microbial peptide
The antimicrobial peptide hLF1-11 comprises the first 11 N-terminal amino acids of the endogenous protein; human lactoferrin. The compound exerts both antibacterial and antifungal activity against a broad range of microorganisms. Moreover, it appears that hLF1-11 has a low propensity to generate resistance in microorganisms, because it acts by stimulating the innate immune system. Phase IIa Proof Of Concept trials have are in preparation in MRSA infections and systemic Candida infections.

Keywords

• Acute Renal Failure
• Ulcerative Colitis
• MRSA
• Systemic candida infection
• Phase II clinical development
• Anti-infective
• Anti-inflammatory
  

AMCAS b.v.
Meibergdreef 45
1105 BA Amsterdam
Website AMCAS b.v.
E-mail AMCAS b.v.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 68

Employees in Amsterdam: 7
Employees in R&D: 5
Year of foundation: 2006

Company Profile

AMCAS is a world wide expert in exploiting an unique model with a human immune system in the fields of infectious diseases, auto-immune diseases and cancer. AMCAS offers this expertise to academic institutes and (bio)pharmaceutical industries.
AMCAS is located on the premises of the Academic Medical Center in Amsterdam, the Netherlands. AMCAS was initiated as a spin out company of this highly experienced scientific research center in the field of immunology and infectious diseases.
AMCAS provides fee-for-service pre-clinical studies using an unique model supporting the development of both the human innate and adaptive immune systems. The model can be manipulated to answer questions linked to developmental biology or treatment purposes (therapeutics and vaccines).

Science and Technologies or Services

AMCAS exploits a HIS(BALB-C-Rag₂^-/-cy^-/-) model (ref: J. Immunology 2006, 176: 2053-2058). This model shows a multi-lineage reconstitution in bone marrow and thymus with peripheral colonisation and development of functional human T-cells in situ.
AMCAS uses high standard facilities and employs or hires personnel with longstanding experience in operating standardised experiments.

Alliances

AMCAS is looking for fee-for-service projects upon assignment by customers having products in pre-clinical development in the field of biologics, vaccines and therapeutics having an anticipated (desired or side) effect on the immune system. Our HIS model can give the customer more detailed information on the anticipated effects of their development compounds on the human immune system in a validated best in class in vivo model.

Amdix B.V. Meibergdreef 45 1105 BA Amsterdam T +31 6 1723 6959 Website Employees in Amsterdam: 1 Employees in R&D: 0 Year of foundation: 2010

Company Profile

Amdix BV is a spin-off company of the Academic Medical Ceneter Amsterdam, focussed on the development and sales of diagnostic products.

Science and Technologies or Services

Alliances

Keywords

Arthrogen B.V.
Meibergdreef 45
1105 BA Amsterdam
Website Arthrogen B.V.
E-mail Arthrogen B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 68

Employees in Amsterdam: 10
Employees in R&D: 9
Year of foundation: 2005

Company Profile

Arthrogen was founded in 2005 as a joint venture of the Academic Medical Center (AMC, Amsterdam, The Netherlands) and the Dubai Bones and Joints Hospital for the clinical and commercial development of an innovative gene therapy approach, developed by researchers of the AMC, as a cure for rheumatoid arthritis locally in the joints. The lead compound will enter phase-I trials in two years.

Science and Technologies or Services

Development of local gene therapy targeting TNF might provide a novel method to treat isolated arthritis activity. This could lead to the development of novel therapeutic strategies targeting primarily the site of inflammation and prevent joint destruction. The gene delivery approach, in addition to other therapeutics, may ultimately provide a more comprehensive treatment for the management of RA. Obviously, achievement of this goal will have a substantial beneficial effect on the RA patient and ultimately on society. Arthrogen aims to develop several innovative medical strategies using gene therapy for local treatment of RA, using several types of cytokines.

Alliances

• Dubai Bones and Joints Center
• Academisch Medisch Centrum Amsterdam
• Galapagos BV
• Agendia BV

Keywords

• Rheumatoid arthritis
• Gene therapy
• Local administration
• Cytokines
  
  
  

BioDetection Systems BV
Science Park 406
1098 XH Amsterdam
Website BioDetection Systems
E-mail BioDetection Systems
T +31 (0)20 435 07 50
F +31 (0)20 435 07 57

Employees in Amsterdam: 17
Employees in R&D: 10
Year of foundation: 2001

Company Profile

BDS is a hybrid-type biotech company, which was founded in 2001 as a spin off from the VU university Amsterdam. BDS is on the one hand an R&D-performing SME developing novel bio-based detection systems, using a functional genomics approach. On the other hand, BDS is and R&D end-user providing service analysis for food safety and environmental quality, and is licensing its technologies to over 40 (inter)national commercial and governmental laboratories in more than 20 different laboratories. BDS has an annual turnover of about 2 million Euros and runs a profit since 2005. BDS, has laboratories for R&D and for service analysis and is located in the high quality facilities of the Amsterdam Science Park at the kruislaan in the east of Amsterdam.

Science and Technologies or Services

Alliances

BDS has collaborative agreements with several allied parties mainly involving distributors and agents to help marketing its products globally. The institute for environmental studies of VU-University is an allied party with respect to analytical chemistry, in addition there are allied partnerships with several other knowledge institutes (WUR, NIOO, RIVM, TNO,KIWA, etc.) mainly within the framework of collaborative R&D projects.

Keywords

• Bioassays
• Fast screening methods
• Food safety
• Environmental quality
• Human monitoring
• (Eco)genomics
• CALUX^®
  
  
  

Bmeye B.V.
AMC, Suite K2-245
Meibergdreef 9
1105 AZ Amsterdam
Website Bmeye
E-mail Bmeye
Promotion video Bmeye
T +31 (0)20 566 58 38
F +31 (0)20 697 64 24

Employees in Amsterdam: 14
Employees in R&D: 8
Year of foundation: 2005

Company Profile

BMEYE is a technology-based company that develops innovative medical devices for the continuous non-invasive monitoring of blood pressure and cardiovascular hemodynamics.
Based on decades of fundamental technology and sensor research, BMEYE is committed to provide researchers, clinicians and patients worldwide with precise, robust, easy-to-use solutions for continuous, entirely non-invasive, cardiovascular monitoring
BMEYE Nexfin®monitors are designed for patient safety first: all measurements are completely non-invasive, with continuous data, no events are missed and with using our comfortable finger sensor, no needles, catheters or injections are needed. The precision of the Nexfin® sophisticated and robust methods provides a full hemodynamic profile with real-time data posted within a minute.

Science and Technologies or Services

Easy diagnosis, effective treatment
Patient responses to diagnostic cardiovascular tests, to interventional devices like pacemakers and to pharmacological treatment with drugs are highly variable and unpredictable, and are often composed of dynamic changes in blood pressure, vascular resistance, stroke volume and cardiac output. Today, their assessment is based on ECG measurements and intermittent standard upper arm NIBP cuff data that misses most if not all of the dynamics of the response.
Integrated continuous measurement of blood pressure and cardiac output in the BMEYE Nexfin® device allows easy and accurate diagnosis and effective follow-up of treatment, and provides the opportunity for immediate feedback to the patient on the effects of therapy and treatment.

Early warning, early and effective response
Patient response to anesthetic agents, cardiovascular drugs and surgical intervention is highly variable and unpredictable, and their combination often induces significant and rapid changes in blood pressure and cardiac output. During surgery, blood pressure monitoring, with the exception of less than 12% of patients who get direct intra-arterial blood pressure monitoring, is accomplished by using a standard cuff-based NIBP monitor, providing only intermittent measurements every 3-5 minutes. Cardiac output monitoring is even absent except in less than  4% of patients who receive pulmonary artery catheter CO monitoring.
Integrated continuous measurement of blood pressure and cardiac output allows early recognition and treatment of rapid changes in hemodynamics (where cardiac output changes usually lead blood pressure changes siginicantly in time) and provides immediate feedback on the impact of interventions for optimal patient management.

Unlike invasive A-lines and PA catheters, which carry a risk of infection or other complications, the BMEYE Nexfin® devices provide an integrated non-invasive solution for continuous blood pressure and cardiac output monitoring. In the OR today, blood pressure and cardiac output are the only critical parameters that are not monitored continuously on all patients. Heart rate, respiration and oxygenation are all monitored continuously and non-invasively for patient safety. The BMEYE Nexfin® technology allows truly complete, integrated and continuous non-invasive vital signs safety monitoring in all patients.

Alliances

• AMC, Amsterdam
• Mayo Clinic, Rochester, MN, USA

Keywords

• Cardiovascular
• Hemodynamics
• Patient Monitoring
• Noninvasive
• Continuous
• Safe
• Precise
• Easy-to-use
• Blood Pressure
• Cardiac Output

Clinical Research Center Echo Pharmaceuticals Jonkerbosplein 52 14e unit A1 6534 AB Nijmegen Website Echo Pharmaceuticals B.V. E-mail Echo Pharmaceuticals B.V. T +31 (0)294 45 73 53 F +31 (0)294 45 73 54 Employees in Amsterdam: 8 Employees in R&D: 6 Year of foundation: 2006

Company profile

The company headquarters are situated in Nijmegen, the Netherlands. The sub-office is in Weesp, the Netherlands.

Science and Technologies or Services

Echo Pharmaceuticals has developed an innovative and patented production process which enables to produce fast soluble tablets containing cannabinoids. Using Purification Technology, Formulation Technology and Encapsulation Technology. We also License our Technology.

Alliances

none

Keywords

• Cannabinoids;
• Purification;
• Development;
• Innovation;
• Formulation;
• Technology.

DC Prime B.V.
De Boelelaan 1085
1081 HV Amsterdam
Website DC Prime B.V.
E-mail DC Prime B.V.
T +31 (0)6 5517 21 58
F +31 (0)20 598 99 04

Employees in Amsterdam: 9
Employees in R&D: 9
Year of foundation: 2005

Company Profile

Science and Technologies or Services

In one arm of its technology base, DCPrime develops sustainable DC lines that can be clinically applied as off-the-shelf DC vaccines. These can be loaded with the desired tumor antigens, but also with viral antigens or antigens for which tolerance is desirable. Also other genes of interest can be introduced into these DC lines without harming their antigen presentation potential, to introduce desirable modulations.
The first DC line, DCOne, is currently being prepared for entering clinical testing, and with several external partners. Scale-up procedures are being developed, and QA/QC compliant dossiers are being built on product specifications, production parameters, harvesting and storage conditions, quality assays, and reproducibility of all processes.
In the second arm of its technology base, DCPrime is performing pre-clinical validation of innovative DC targeting tools that can be directly applied to skin. The technological basis for these products will be prepared for strategic collaborations with co-development partners.

Alliances

DCPrime BV works together with the VU medical center, and with many life sciences companies and CRO’s in Europe.

Keywords

• Cancer
• Immunotherapy
• Autoimmunity
• Dendritic cells
  
  
  

DC4U B.V.
Van der Boechorststraat 7
1081 BT Amsterdam
E-mail DC4U B.V.
T +31 (0)20 444 80 84
F +31 (0)20 444 80 81

Year of foundation: 2006

Company Profile

Science and Technologies or Services

Recently, glycomics research has yielded potential leads that may provide innovative solutions for the treatment of cancer. Glycomics is a new biomedical discipline that investigates how sugar modification of macromolecules (glycosylation) affects their biological and pathological function. Recent exciting discoveries in this field, in which Prof. Dr. Y. van Kooyk has a world-leading role, are further explored. DC4U B.V. strongly believes that liposomes containing highly specific APC-targeting signals using glycans provide the answer in the search for a new vaccine to cure colon cancer. The fact that certain glycans can target two different APC subsets allows us for the first time to design a vaccine that targets both subsets that have strong immune-modulating capacity.

Alliances

• Drug Discovery Factory B.V.
• VU Medical Center Amsterdam
• Octoplus Technologies B.V.
• Utrecht University
• Technical University Munchen

Keywords

• Cancer
• Therapeutics
• Vaccines
• Immunotherapy
• Autoimmunity
• Dendritic Cells
• Drug Discovery

DEAM Corporation
Science Park 400
1098 XH Amsterdam
Website DEAM Corporation
E-mail DEAM Corporation
Promotion video DEAM Corporation
T +31 (0)20 717 3810
F +31 (0)84 225 29 63

Employees in Amsterdam: 3
Employees in R&D: 3
Year of foundation: 2005

Company Profile

DEAM develops and manufactures instruments for minimally invasive therapies.

Science and Technologies or Services

DEAM has extensive knowledge on steering technology for use in instruments for minimally invasive therapies. It has an own patent database covering an unique steering mechanism that can be used in rigid or flexible instruments having diameters ranging from 0,5 to 11 mm.
DEAM develops and manufactures steerable instruments on their own or on customer demand.
Current product development is focussed on instruments for laparoscopic procedures, cardiology and eye surgery.

Alliances

Keywords

• Steerable
• Surgical
• Instrument
• Minimally
• Invasive
  
  

Drug Discovery Factory BV
Albrechtlaan 14a
1404 AK Bussum
Website Drug Discovery Factory B.V.
E-mail Drug Discovery Factory B.V.
T +31 (0)35 695 40 50

Employees in Amsterdam: 14
Employees in R&D: 10
Year of foundation: 2003

Company profile

Currently the DDF group consists of 12 companies in the life sciences Using a hands-on approach and dedication to meet customer demands we aim to create value for our clients and other stakeholders. Peter Schoevers and Henk Viëtor, the founders of DDF, have established themselves as two of the leading Life Sciences entrepreneurs behind successful companies such as Recharge, DCPrime, Skyline Diagnostics, Dynomics and Julius Clinical Research.

Science and Technologies or Services

Selecting
DDF selects the most attractive research projects at leading University Medical Center and other research institutions.

Financing
DDF provides and/or organizes funding and grants.

Managing
DDF monitors the projects, files patents, finds partners, provides (project) management.

Commercialising
DDF markets and sells projects, products and services.

Consulting
The team of 14 employees of DDF undertakes management activities, consultancy activities, IP management and financial administration activities.

Alliances

We have a dedicated network of partners to realize research and development projects and work closely with academic hospitals, regulatory authorities and local and national governments.

Keywords

• Drug development;
• University;
• Intellectual property;
• Consultancy;
• Entrepreneurship;
• Commercialisation.

Dynomics B.V.
P.O. Box 82
1400 AB Bussum
Website Dynomics B.V.
E-mail Dynomics B.V.
T +31 (0)10 704 40 94
F +31 (0)10 704 47 31

Employees in Amsterdam:
Employees in R&D:
Year of foundation: 2001

Company Profile

Science and Technologies or Services

Alliances

Keywords

• Leukemia
• Lymphomas
• Cancer
• Fusion Proteins
• Drug Discovery
• Diagnostics.